Abstract:Objectives: Genetic or acquired defects in FOXP3+ regulatory T cells (Tregs) play a key role in many immune-mediated diseases including immune dysregulation polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome. Previously, we demonstrated CD4+ T cells from healthy donors and IPEX patients can be converted into functional Treg-like cells by lentiviral transfer of FOXP3 (CD4LVFOXP3). These CD4LVFOXP3 cells have potent regulatory function, suggesting their potential as an innovative therapeutic. Here, we present molecular and preclinical in vivo data supporting CD4LVFOXP3 cell clinical progression. Methods: The molecular characterisation of CD4LVFOXP3 cells included flow cytometry, qPCR, RNA-seq and TCR-seq. The in vivo suppressive function of CD4LVFOXP3 cells was assessed in xenograft-versus-host disease (xeno-GvHD) and FOXP3-deficient IPEX-like humanised mouse models. The safety of CD4LVFOXP3 cells was evaluated using peripheral blood (PB) humanised (hu)- mice testing their impact on immune response against pathogens, and immune surveillance against tumor antigens. Results: We demonstrate that the conversion of CD4+ T cells to CD4LVFOXP3 cells leads to specific transcriptional changes as compared to CD4+ T-cell transduction in the absence of FOXP3, including upregulation of Treg-related genes. Furthermore, we observe specific preservation of a polyclonal TCR repertoire during in vitro cell production. Both allogeneic and autologous CD4LVFOXP3 cells protect from xeno-GvHD after two sequential infusions of effector T cells. CD4LVFOXP3 cells prevent hyper-proliferation of CD4+ memory T cells in the FOXP3-deficient IPEX-like hu-mice. CD4LVFOXP3 cells do not impede in vivo expansion of antigen-primed T cells or tumor clearance in the PB hu-mice. Conclusion: These data support the clinical readiness of CD4LVFOXP3 cells to treat IPEX syndrome and other immune-mediated diseases caused by insufficient or dysfunctional FOXP3+ Tregs.

A Structure-Guided Delineation of FOXP3 Regulation Mechanism in IPEX.

FOXP3 and Its Partners: Structural and Biochemical Insights into the Regulation of FOXP3 Activity

Structural and biological features of FOXP3 dimerization relevant to regulatory T cell function.

Molecular Feature and Therapeutic Perspectives of Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-linked Syndrome

FOXP3 Activation in Treg Cells, - Atomic Level Aspects of FOXP3 Structure and Biochemistry That Govern Function (89.4)

Identification of unstable regulatory and autoreactive effector T cells that are expanded in patients with FOXP3 mutations

FoxP3 in T reg cell biology: a molecular and structural perspective

Structural Aspects of the FOXP3 Regulatory Complex As an Immunopharmacological Target

FoxP3 in Treg Cell Biology: a Molecular and Structural Perspective

FOXP3 Exon 2 Controls Treg Stability and Autoimmunity

FoxP3 in T<sub>reg</sub> cell biology: a molecular and structural perspective

FOXP3 exon 2 controls T reg stability and autoimmunity

From IPEX syndrome to FOXP3 mutation: a lesson on immune dysregulation

The regulation of immune tolerance by FOXP3

Foxp3+ Regulatory T Cells: a Protagonist in the “movie’’ of Autoimmune Diseases?

FOXP3 is a Homo-Oligomer and a Component of a Supramolecular Regulatory Complex Disabled in the Human XLAAD/IPEX Autoimmune Disease.

Molecular and biological role of the FOXP3 N-terminal domain in immune regulation by T regulatory/suppressor cells.

Molecular Mechanisms Underlying the Regulation and Functional Plasticity of FOXP3 + Regulatory T Cells

Human-engineered Treg-like cells suppress FOXP3-deficient T cells but preserve adaptive immune responses in vivo

Biochemistry and therapeutic implications of mechanisms involved in FOXP3 activity in immune suppression.

Ltargeting FOXP3 Complex Ensemble in Drug Discovery